Study S003335

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CT-996 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT05814107
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 94
Start: 2023-05-09
Primary completion: 2025-11-07
Lead sponsor: Carmot Australia First Pty Ltd
Conditions: Type 2 Diabetes; Overweight or Obesity
Interventions: DRUG:CT-996; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of Treatment-Emergent Adverse Events [From first study drug administration until last safety follow-up (up to 31 days [Part 1] or 58 days [Parts 2 and 3])]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.